Chronic lymphocytic leukaemia
RecruitingStudy on Treating Chronic Lymphocytic Leukemia with Venetoclax and Acalabrutinib for Patients Whose Disease Has Returned After Initial Treatment
Study on Treating Chronic Lymphocytic Leukemia with Venetoclax and Acalabrutinib for Patients Whose Disease Has Returned After Initial Treatment
- Disease:Chronic lymphocytic leukaemia
- Substances:AcalabrutinibVenetoclax
Belgium- Participants:18–64 years · 65+ years
- Substances:Acalabrutinib
- Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting













